I recall looking at that, when they were still called Suda (SUD.ASX).
but it’s really chalk and cheese in terms of the quality of the asset, though I can only assume because there were no journals or publications that I could find on what SUD licensed… as it was only preclinical, compared to what CHM can license, where the phase 1 trial is reading out mid next year. And where the inventor won an prestigious award for his work, as well as a publication in Nature talking about his work.
SUD also had no synergistic assets of their own that I was aware of to make it truly transformational… rather it was more of a stand-alone new business venture.
again compare that to what CHM are doing, first they are going to make a next gen NK of the already enhanced NK cell.
they are then going to take that next gen NK and create three NK-CARs, using existing and undisclosed targeting domains, which CHM has rights to and clinical trials are underway or soon to be underway.
so transformational to me means taking what you already had and totally changing the trajectory and direction of your entire business. CHM have done just that.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)